Cholesterol-Lowering Antibody Evinacumab Halves LDL Across Lipid Disorders
A systematic review and meta-analysis of 17 studies finds that the ANGPTL3-blocking antibody evinacumab cuts LDL cholesterol by roughly half ...
A systematic review and meta-analysis of 17 studies finds that the ANGPTL3-blocking antibody evinacumab cuts LDL cholesterol by roughly half ...
A five-year Japanese cohort study finds that nocturnal oxygen desaturation roughly doubles the risk of developing metabolic syndrome in adults ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine